Cell Therapeutics receives Fast Track Designation for Pixantrone.

Singer, M.D., Chief Medical Officer of CTI. The pivotal trial is definitely well-designed and if effective, the efficacy and cardiac protection profile combined with the drug’s administration advantages could make pixantrone a significant therapeutic for the potential treatment of intense NHL. Fast monitor designation for pixantrone can be an important part of the development of this product candidate and may help us provide this potentially life-saving drug to sufferers more quickly, mentioned James A. Bianco, M.D., President and CEO of CTI. Pixantrone can be presently becoming studied as a single-agent and in combination in several phase I and II clinical studies for the potential treatment of intense or indolent NHL.As a result, they are urging parents and pediatricians to look for symptoms of the problem. In 2006, 150 children at Nationwide Children’s, seven % of most speech therapy patients, were identified as having apraxia of speech. That’s more than double the entire year before. Meanwhile, the number of speech pathology sufferers overall increased by simply 13 % from 2005 to 2006. While there is little national data available representing the true number of kids with apraxia of speech, speech therapists at Nationwide Children’s estimate as much as one to 10 children out of every 1,000 kids might have the disorder. Related StoriesNew UCLA research looks at primary care medical house in reducing childrens' repeat appointments to hospitalsCHOP's Buerger Center for Advanced Pediatric Treatment celebrates grand openingLoyola Medicine, Palos Community Hospital jointly launch innovative telemedicine programChildren with apraxia of speech know what they want to state, but their brains have a problem coordinating the muscle actions of the lips, jaw and tongue necessary to say those words.